Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-85 (Canceled).

86. [Currently Amended] A method for treating Parkinson's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Parkinson's disease in said subject is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ICE inhibitors, neuroimmunophilis, N-acetylcysteine, antioxidants, lipoic acid, cofactors, riboflavin, and CoQ10, wherein said creatine compound has the formula:



and pharmaceutically acceptable salts thereof, wherein:

a) Y is ~~selected from the group consisting of:~~ $-CO_2H$~~, -NHOH, $N0_2$, SO_3H, C(=0)NHS0_2J and P(=O)(OH)(OJ), wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight chain alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl~~;

b) A is selected from the group consisting of: C, CH, C_1-C_5alkyl, C_2-C_5alkenyl, C_2-C_5alkynyl, and C_1-C_5 alkoyl chain, each having 0-2 substituents which are selected independently from the group consisting of:

1) K, where K is selected from the group consisting of: C_1 -C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl,

C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~2) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy; and~~

2~~3~~) -NH-M, wherein M is selected from the group consisting of: hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_1-C_4 alkoyl, C_3-C_4 branched alkyl, C_3-C_4 branched alkenyl, and C_4 branched alkoyl;

c) X is ~~selected from the group consisting of~~ NR_1~~, CHR_1, CR_1, O and S~~, wherein R_1 is selected from the group consisting of:

1) hydrogen;

2) K where K is selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~3) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;~~

~~4) a C_5-C_9 a-amino-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon;~~

~~5) a C_5-C_9 a-amino-w-aza-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon; and~~

~~6) a C_5-C_9 a-amino-w-thia-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon;~~

d) Z_1 and Z_2 are chosen independently from the group consisting of: ~~=0,~~ $-NHR_2$, ~~$-CH_2R_2$, $-NR_2OH$; wherein Z_1 and Z_2 may not both be =0 and~~ wherein R_2 is selected from the group consisting of:

1) hydrogen;

2) K, where K is selected from the group consisting of: C_1-C_6 straight alkyl; C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~3) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;~~

3~~4~~) a C_4-C_8 a-amino-carboxylic acid attached via the w-carbon; and

4~~5~~) B, wherein B is selected from the group consisting of: $-CO_2H$, -NHOH, $-SO_3H$, and $-N0_2$, ~~OP(=O)(OH)(OJ) and P(=O)(OH)(OJ)~~, wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl, wherein B is optionally connected to the nitrogen via a linker selected from the group consisting of: C_1-C_2 alkyl, C_2 alkenyl, and C_1-C_2 alkoyl.~~;~~

~~6) D-E, wherein D is selected from the group consisting of: C_1-C_3 straight alkyl, C_3 branched alkyl, C_2-C_3 straight alkenyl, C_3 branched alkenyl, C_1-C_3 straight alkoyl, aryl and aroyl; and E is selected from the group consisting of: $-(P0_3)_n$NMP, where n is 0-2 and NMP is ribonucleotide monophosphate connected via the 5' phosphate, 3' phosphate or the aromatic ring of the base; $[P(=O)(OCH_3)(0)]_m$-Q, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; $[P(=O)(OH)(CH_2)]_m$-Q, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; and an aryl group containing 0-3 substituents chosen independently from the group consisting of: Cl, Br, epoxy, acetoxy, -OG, C(=O)G, and $-CO_2G$, where G is independently selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched~~

~~alkyl, C_3-C_6 branched alkenyl, C_4-C_6 branched alkoyl, wherein E may be attached to any point to D, and if D is alkyl or alkenyl, D may be connected at either or both ends by an amide linkage; and~~

~~7) E, wherein E is selected from the group consisting of $(P0_3)_n$NMP, where n is 0-2 and NMP is a ribonucleotide monophosphate connected via the 5' phosphate, 3' phosphate or the aromatic ring of the base; $[P(=O)(OCH_3)(0)]_m$-Q, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; $[P(=O)(OH)(CH_2)]_m$-Q, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; and an aryl group containing 0-3 substituents chose independently from the group consisting of: C_1, Br, epoxy, acetoxy, -OG, -C(=O)G, and -CO=G, where G is independently selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, C_4-C_6 branched alkoyl; and if E is aryl, E may be connected by an amide linkage;~~

~~e) if R_1 and at least one R_2 group are present, R_1 may be connected by a single or double bond to an R_2 group to form a cycle of 5 to 7 members;~~

~~f) if two R_2 groups are present, they may be connected by a single or a double bond to form a cycle of 4 to 7 members; and~~

~~g) if R_1 is present and Z_1 or Z_2 is selected from the group consisting of NHR_2, CH_2R_2 and NR_2OH, then R_1 may be connected by a single or double bond to the carbon or nitrogen of either Z_1 or Z_2 to form a cycle of 4 to 7 members.~~

Claims 87-90 (Cancelled).

91. [Currently Amended] The method of claim 86 or 133, wherein said neuroprotective agent is a spin trap.

92. [Previously Presented] The method of claim 91, wherein said spin trap is PBN.

93. [Currently Amended] The method of claim 86 or 133, wherein said neuroprotective agent is a cofactor for normal cellular metabolism.

94. [Previously Presented] The method of claim 93, wherein said cofactor is carnitine.

95. [Currently Amended] The method of claim 86 or 133, wherein said neuroprotective agent is an antioxidant.

96. [Previously Presented] The method of claim 95, wherein said antioxidant is vitamin E.

97. [Cancelled]

98. [Currently Amended] The method of claim 86 or 133, wherein said neuroprotective agent is riboflavin.

99. [Currently Amended] The method of claim 86 or 133, further comprising administering at least one additional neuroprotective agent or creatine compound.

100. [Currently Amended] The method of claim 86 or 133, wherein said creatine compound is creatine.

Claims 101-107 (Canceled).

108. [Currently Amended] A method for treating Huntington's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Huntington's disease is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ICE inhibitors, neuroimmunophilis, N-acetylcysteine, antioxidants, lipoic acid, cofactors, riboflavin, and CoQ10, wherein said creatine compound has the formula:



and pharmaceutically acceptable salts thereof, wherein:

a) Y is ~~selected from the group consisting of:~~ $-CO_2H$~~, -NHOH, $N0_2$, SO_3H, C(=0)$NHS0_2$J and P(=O)(OH)(OJ), wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight chain alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl~~;

b) A is selected from the group consisting of: C, CH, C_1-C_5alkyl, C_2-C_5alkenyl, C_2-C_5alkynyl, and C_1-C_5 alkoyl chain, each having 0-2 substituents which are selected independently from the group consisting of:

1) K, where K is selected from the group consisting of: C_1 -C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~2) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy; and~~

2~~3~~) -NH-M, wherein M is selected from the group consisting of: hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_1-C_4 alkoyl, C_3-C_4 branched alkyl, C_3-C_4 branched alkenyl, and C_4 branched alkoyl;

c) X is ~~selected from the group consisting of~~ NR_1~~, CHR_1, CR_1, O and S~~, wherein R_1 is selected from the group consisting of:

1) hydrogen;

2) K where K is selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6

branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~3) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;~~

~~4) a C_5-C_9 a-amino-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon;~~

~~5) a C_5-C_9 a-amino-w-aza-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon; and~~

~~6) a C_5-C_9 a-amino-w-thia-w-methyl-w-adenosylcarboxylic acid attached via the w-methyl carbon;~~

d) Z_1 and Z_2 are chosen independently from the group consisting of: ~~=0,~~ $-NHR_2$, ~~$-CH_2R_2$, $-NR_2OH$; wherein Z_1 and Z_2 may not both be =0 and~~ wherein R_2 is selected from the group consisting of:

1) hydrogen;

2) K, where K is selected from the group consisting of: C_1-C_6 straight alkyl; C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, and C_4-C_6 branched alkoyl, K having 0-2 substituents independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;

~~3) an aryl group, wherein the aryl group is a 1-2 ring carbocycle and contains 0-2 substituents independently selected from the group consisting of: $-CH_2L$ and $-COCH_2L$ where L is independently selected from the group consisting of: bromo, chloro, epoxy and acetoxy;~~

3~~4~~) a C_4-C_8 a-amino-carboxylic acid attached via the w-carbon; and

~~4~~5) B, wherein B is selected from the group consisting of: -CO_2H, -NHOH, -SO_3H, and -$N0_2$, ~~OP(=O)(OH)(OJ) and P(=O)(OH)(OJ)~~, wherein J is selected from the group consisting of: hydrogen, C_1-C_6 straight alkyl, C_3-C_6 branched alkyl, C_2-C_6 alkenyl, C_3-C_6 branched alkenyl, and aryl, wherein B is optionally connected to the nitrogen via a linker selected from the group consisting of: C_1-C_2 alkyl, C_2 alkenyl, and C_1-C_2 alkoyl.~~;~~

~~6) D E, wherein D is selected from the group consisting of: C_1-C_3 straight alkyl, C_3 branched alkyl, C_2-C_3 straight alkenyl, C_3 branched alkenyl, C_1-C_3 straight alkoyl, aryl and aroyl; and E is selected from the group consisting of: $-(P0_3)_nNMP$, where n is 0-2 and NMP is ribonucleotide monophosphate connected via the 5' phosphate, 3' phosphate or the aromatic ring of the base; $-[P(=O)(OCH_3)(0)]_m-Q$, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; $-[P(=O)(OH)(CH_2)]_m-Q$, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; and an aryl group containing 0-3 substituents chosen independently from the group consisting of: Cl, Br, epoxy, acetoxy, -OG, -C(=O)G, and $-CO_2G$, where G is independently selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, C_4-C_6 branched alkoyl, wherein E may be attached to any point to D, and if D is alkyl or alkenyl, D may be connected at either or both ends by an amide linkage; and~~

~~7) E, wherein E is selected from the group consisting of $-(P0_3)_nNMP$, where n is 0-2 and NMP is a ribonucleotide monophosphate connected via the 5' phosphate, 3' phosphate or the aromatic ring of the base; $-[P(=O)(OCH_3)(0)]_m-Q$, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; $-[P(=O)(OH)(CH_2)]_m-Q$, where m is 0-3 and Q is a ribonucleoside connected via the ribose or the aromatic ring of the base; and an aryl group containing 0-3 substituents chose independently from the group consisting of: C_1, Br, epoxy, acetoxy, -OG, -C(=O)G, and -CO=G, where G is independently selected from the group consisting of: C_1-C_6 straight alkyl, C_2-C_6 straight alkenyl, C_1-C_6 straight alkoyl, C_3-C_6 branched alkyl, C_3-C_6 branched alkenyl, C_4-C_6 branched alkoyl; and if E is aryl, E may be connected by an amide linkage;~~

~~e) if R_1 and at least one R_2 group are present, R_1 may be connected by a single or double bond to an R_2 group to form a cycle of 5 to 7 members;~~

~~f) if two R_2 groups are present, they may be connected by a single or a double bond to form a cycle of 4 to 7 members; and~~

~~g) if R_1 is present and Z_1 or Z_2 is selected from the group consisting of NHR_2, CH_2R_2 and NR_2OH, then R_1 may be connected by a single or double bond to the carbon or nitrogen of either Z_1 or Z_2 to form a cycle of 4 to 7 members.~~

Claims 109-112 (Cancelled).

113. [Currently Amended] The method of claim 108 or 134, wherein said neuroprotective agent is a spin trap.

114. [Previously Presented] The method of claim 113, wherein said spin trap is PBN.

115. [Currently Amended] The method of claim 108 or 134, wherein said cofactor is a cofactor for normal cellular metabolism.

116. [Previously Presented] The method of claim 115, wherein said cofactor is carnitine.

117. [Currently Amended] The method of claim 108 or 134, wherein said neuroprotective agent is an antioxidant.

118. [Previously Presented] The method of claim 117, wherein said antioxidant is vitamin E.

119. [Cancelled].

120. [Previously Presented] The method of claim 117, wherein said neuroprotective agent is riboflavin.

121. [Currently Amended] The method of claim 108 or 134, further comprising administering at least one additional neuroprotective agent or creatine compound.

122. [Currently Amended] The method of claim 108 or 134, wherein said creatine compound is creatine.

Claim 123-132 (Canceled).

133. [New] A method for treating Parkinson's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Parkinson's disease in said subject is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ICE inhibitors, neuroimmunophilis, N-acetylcysteine, antioxidants, lipoic acid, cofactors, riboflavin, and CoQ10, wherein said creatine compound is selected from the group consisting of:


,

,

,

,

,

,

,

, and pharmaceutically acceptable salts thereof.

134. [New] A method for treating Huntington's disease in a subject, comprising:

administering to a subject a therapeutically effective amount of a combination of creatine, a creatine phosphate or a creatine compound and a neuroprotective agent, such that Huntington's disease is treated, wherein said neuroprotective agent is selected from the group consisting of inhibitors of glutamate excitotoxicity, 2,3 dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ICE inhibitors, neuroimmunophilis, N-acetylcysteine, antioxidants, lipoic acid, cofactors, riboflavin, and CoQ10, wherein said creatine compound is selected from the group consisting of:


,

,

,

,

,

,

, and pharmaceutically acceptable salts thereof.